The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Abstract
Cyclin-dependent kinases (Cdks) are serine/threonine kinases and their catalytic activities are modulated by interactions with cyclins and Cdk inhibitors (CKIs). Close cooperation between this trio is necessary for ensuring orderly progression through the cell cycle. In addition to their well-established function in cell cycle control, it is becoming increasingly apparent that mammalian Cdks, cyclins and CKIs play indispensable roles in processes such as transcription, epigenetic regulation, metabolism, stem cell self-renewal, neuronal functions and spermatogenesis. Even more remarkably, they can accomplish some of these tasks individually, without the need for Cdk/cyclin complex formation or kinase activity. In this Review, we discuss the latest revelations about Cdks, cyclins and CKIs with the goal of showcasing their functional diversity beyond cell cycle regulation and their impact on development and disease in mammals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“This increased Cdk complexity is thought to satisfy the requirement for a more elaborate control over the proliferation of different cell types during the advancement from unicellular to complex multicellular organisms (Malumbres and Barbacid, 2009).”
BackgroundThe cell biology of neurogenesis
Götz, M., & Huttner, W. B. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1739 · Cited by 2,130
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153
CDK inhibitors: Cell cycle regulators and beyond
Besson, A., Dowdy, S. F., & Roberts, J. M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.013 · Cited by 1,152
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Cell-cycle control and cortical development
Dehay, C., & Kennedy, H. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2097 · Cited by 655 · cited 1×
“However, it remains unclear how prolonging G1 induces differentiation mechanistically, other than the hypothesis that because G1 is the period of the cell cycle in which cells are exposed to extrinsic differentiating stimuli, spending more time in G1 should arguably lead to an accumulation of cell fate determinants to…”
BackgroundBlazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., Parks, B., Gars, E., Liedtke, M., Zheng, G. X. Y., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0332-7 · Cited by 498
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
FOXO transcription factor family in cancer and metastasis
Jiramongkol, Y., & Lam, E. W.-F. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09883-w · Cited by 281
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
Richters, A., Doyle, S. K., Freeman, D. B., Lee, C., Leifer, B. S., Jagannathan, S., Kabinger, F., Koren, J. V., Struntz, N. B., Urgiles, J., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.10.001 · Cited by 86
Immunomodulatory Roles of Cell Cycle Regulators
Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71
Hasenpusch-Theil, K., West, S., Kelman, A., Kozic, Z., Horrocks, S., McMahon, A. P., Price, D. J., Mason, J. O., & Theil, T. (2018) · Development · doi:10.1242/dev.163147 · Cited by 54
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
Witkiewicz, A. K., Borja, N. A., Franco, J., Brody, J. R., Yeo, C. J., Mansour, J., Choti, M. A., McCue, P., & Knudsen, E. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3819 · Cited by 56
Li, A., Fan, S., Xu, Y., Meng, J., Shen, X., Mao, J., Zhang, L., Zhang, X., Moeckel, G., Wu, D., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13091 · Cited by 42
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Dixon-Clarke, S. E., Elkins, J. M., Cheng, S.-W. G., Morin, G. B., & Bullock, A. N. (2015) · Scientific Reports · doi:10.1038/srep17122 · Cited by 38
Chiarelli, N., Carini, G., Zoppi, N., Ritelli, M., & Colombi, M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211647 · Cited by 35
Inhibition of acetylation, is it enough to fight cancer?
López-Bañuelos, L., & Vega, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103752 · Cited by 32
The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2
Willmer, T., Peres, J., Mowla, S., Abrahams, A., & Prince, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1080398 · Cited by 32
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01475-z · Cited by 24
Liu, Y., Tang, Q., Tao, Q., Dong, H., Shi, Z., & Zhou, L. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.024 · Cited by 18
KIR+ CD8+ T Lymphocytes in Cancer Immunosurveillance and Patient Survival: Gene Expression Profiling
Gimeno, L., Serrano-López, E. M., Campillo, J. A., Cánovas-Zapata, M. A., Acuña, O. S., García-Cózar, F., Martínez-Sánchez, M. V., Martínez-Hernández, M. D., Soto-Ramírez, M. F., López-Cubillana, P., et al. (2020) · Cancers · doi:10.3390/cancers12102991 · Cited by 17
Tokumoto, Y., Tamaki, S., Kabe, Y., Takubo, K., & Suematsu, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-01023-9 · Cited by 16
Xie, P., Wang, H., Xie, J., Huang, Z., Chen, S., Cheng, X., Zhang, X., Liu, F., Li, Y., & Huang, D. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111037 · Cited by 16
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Metadata
- Authors
- Lim, S., & Kaldis, P.
- Venue
- Development
- Publisher
- The Company of Biologists
- Published
- 2013-08-01
- Volume
- 140
- Issue
- 15
- Pages
- 3079-3093
- ISSN
- 0950-1991 (ISSN-L)
- 1477-9129
- OpenAlex
- W1985139403
- Cited by
- 1,487
- References
- 16
- FWCI
- 41.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
